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Abstract 
 
Background:  Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a significant cause 
of sudden cardiac death in the young. Improved noninvasive assessment of ARVC and better 
understanding of the disease substrate are important for improving patient outcomes. 
 
Methods and Results:  We studied 20 genotyped ARVC patients with a broad spectrum of 
disease using Electrocardiographic Imaging (ECGI; a method for noninvasive cardiac 
electrophysiology (EP) mapping) and advanced late gadolinium enhancement (LGE) cardiac 
magnetic resonance scar imaging.  Compared to 20 healthy controls, ARVC patients had longer 
ventricular activation duration (median 52 vs 42 ms; p = 0.007) and prolonged mean epicardial 
activation-recovery intervals (a surrogate for local action potential duration; median 275 vs 241 
ms; p = 0.014). In these patients, we observed abnormal and varied epicardial activation 
breakthrough locations, and regions of non-uniform conduction and fractionated electrograms. 
Non-uniform conduction and fractionated electrograms were present in the early concealed phase 
of ARVC. EP abnormalities co-localized with LGE scar, indicating a relationship with structural 
disease. Premature ventricular contractions (PVCs) were common in ARVC patients with 
variable initiation sites in both ventricles. PVC rate increased with exercise, and within 
anatomical segments it correlated with prolonged repolarization, electrical markers of scar, and 
LGE (all p < 0.001). 
 
Conclusions: ECGI reveals EP substrate properties that differ in ARVC patients compared to 
healthy controls. A novel mechanistic finding is the presence of repolarization abnormalities in 
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regions where ventricular ectopy originates. The results suggest a potential role for ECGI and 
LGE in early diagnosis and non-invasive follow-up of ARVC patients. 
 
Key Words: 
arrhythmogenic right ventricular cardiomyopathy, electrocardiographic imaging, late gadolinium 
enhancement 
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Arrhythmogenic right ventricular cardiomyopathy (ARVC) [abbreviations are defined in 
Supplemental Table S1] is an important hereditary cause of sudden cardiac death in young 
individuals with an estimated prevalence as high as 1:1000 1,2. The ARVC phenotype is 
progressive, consisting of an early concealed phase, overt arrhythmias, and heart failure. 
However, penetrance is variable and the first manifestation of the disease may be sudden cardiac 
death 1,2. Diagnosis and treatment of ARVC are challenging, with implications for family 
screening and risk stratification 3,4.  
 
ARVC is characterized by fibro-fatty infiltration of the myocardium with an epicardial 
predominance, suggesting that the disease progresses from epicardium to endocardium 5. Fibro-
fatty replacement in ARVC results from desmosomal mutations that lead to progressive 
cardiomyocyte death 6. The desmosomal mutations cause decreased function of sodium channels 
and gap junctions in cardiomyocytes 6,7. Exercise hastens disease progression by elevating 
myocardial wall stress, especially in the right ventricle (RV) 8, and has been linked to episodes of 
sudden cardiac death. Human and murine studies demonstrated that electrophysiological changes 
precede the structural disease 9. Though originally described as a RV disease, there is increasing 
evidence for non-classical presentation with both biventricular and left ventricular (LV)-
dominant disease 10. 
 
Definitive diagnosis of ARVC requires histological demonstration of fibrofatty replacement of 
myocardium or the presence of a known ARVC genotype. Biopsy is challenging because the 
fibro-fatty infiltration may be patchy and epicardial. Genotypes linked to ARVC are present in 
only 30-40% of cases. Current diagnosis utilizes a combination of structural, functional, and 
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electrophysiological (EP) criteria 3. However, diagnosis is challenging because of the progressive 
nature of ARVC and its early concealed phase. The only treatment proven to prevent sudden 
cardiac death in ARVC patients is the implantable cardioverter defibrillator (ICD). However, 
ICD implantation carries risks, and primary prevention indications remain a matter of debate 4,11. 
 
Effective non-invasive modalities and improved understanding of ARVC arrhythmia 
mechanisms are essential for accurate diagnosis and risk stratification. As stated in a recent 
editorial, access to the epicardium for electrical measurements can enhance earlier disease 
detection. However, direct epicardial access is challenging and limited to experienced clinical 
centers 12. The present study employs a noninvasive method (Electrocardiographic Imaging: 
ECGI; also referred to as Electrocardiographic Mapping (ECM) or body-surface mapping) 13 for 
epicardial EP mapping and the latest generation of magnetic resonance imaging (MRI) for 
cardiac structure (cardiac MRI (CMR) with advanced late gadolinium enhancement (LGE) using 
motion correction reconstruction) 14. We applied ECGI and LGE to study the electrical and 
structural substrates in ARVC patients. These two techniques are safe, noninvasive, and well 
suited to longitudinal assessment of ARVC patients. The goal of this study is to provide insight 
into the myocardial substrate and arrhythmia mechanisms in ARVC. It also constitutes a 
preliminary exploration of the suitability of combined ECGI and LGE for diagnosis and risk 
stratification of ARVC patients. 
 
Methods 
Patient Cohort 
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Twenty ARVC patients with a broad spectrum of structural and electrophysiological disease 
were enrolled at the Heart Hospital, UCLH, London, UK. All patients were genotyped for 
desmosomal mutations. Patient characteristics are summarized in Table 1 (additional clinical 
characteristics provided in Supplemental Tables S2 and S3). The study was approved by the 
National Research Ethics Service Committee London (14/LO/0360) and the Human Research 
Protection Office at Washington University in St. Louis. All patients provided written informed 
consent. The study conformed to the declaration of Helsinki. 
 
ECGI and MRI  
The ECGI method was developed and validated in our laboratory and described previously 13. A 
schematic of the procedure is presented in Supplemental Figure S1. Briefly, 256 uniformly 
distributed body-surface electrocardiograms (ECGs) were recorded simultaneously using a 
portable recording system (ActiveTwo, BioSemi, Netherlands). Patients exercised on a supine 
ergometer for two minutes, followed by a ramp protocol of fifteen Watts/minute to a maximum 
heart rate (HR) of 120 beats/minute. Recordings were performed in the supine position at rest, 
during exercise, and immediately following exercise cessation. ECGI data were transferred to the 
Rudy lab for data processing, map construction, and analysis. 
 
Following the recording protocol, CMR was performed in a 1.5 T scanner (Magnetom Avanto, 
Siemens Medical Solutions, Germany). Prior to the scan, recording electrodes were replaced 
with MRI-visible markers so the electrode positions could be obtained in the same coordinate 
system as the heart geometry. A navigated anatomical sequence was used so the ECGI electrical 
and anatomical data could be merged. Conventional cine imaging and advanced LGE imaging 
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were conducted following the thorax scan. The contrast agent was 0.1mmol/Kg of Gadoterate 
meglumine (Dotarem, Guerbet S.A., Paris, France) with LGE images acquired 5-15 minutes 
post-contrast. The LGE sequence was a single shot steady state free precession phase sensitive 
inversion recovery sequence 14 with motion corrected averaging and high resolution (typical 
matrix: 144 x 256; voxel size 2.0 x 1.5 x 6.0 mm3). Two patients declined contrast injection. 
 
Unipolar epicardial electrograms (EGMs) were reconstructed using previously described 
methods 13 (additional ECGI methodology references in Supplement). Briefly, the heart-torso 
geometry obtained from the MRI was used to compute a transfer matrix relating epicardial 
potentials to torso potentials. The inverse problem was solved to compute epicardial EGMs from 
the recorded ECGs. Typically, 1000 EGMs were computed over the entire ventricular 
epicardium. EGMs over the valve plane were excluded from analysis. Epicardial activation and 
repolarization maps were constructed from the EGMs. ECGI reconstructions of sinus rhythm 
were computed for each patient at resting HR prior to exercise and at elevated HR immediately 
after exercise cessation. Additionally, the epicardial activation sequence was computed for each 
unique premature ventricular contraction (PVC) morphology observed. 
 
Analysis 
Segmentation 
ECGI maps and LGE images for each patient’s ventricles were divided into basal, mid, and 
apical regions. Basal and mid regions were further subdivided into anterior, anterolateral, 
inferolateral, and inferior regions. Apical regions were subdivided into anterior and inferior 
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regions. EGM measures for each region were computed as the mean value from all EGMs within 
the region. 
 
CMR Analysis 
CMR analysis was performed using CVI42 software (Circle Cardiovascular Imaging 
Inc.,Version 5.1.2[303], Calgary, Canada). For the analysis of LGE in the LV, epicardial and 
endocardial borders were manually drawn on the short axis slices and the anterior RV insertion 
point was identified. The Otsu semi-automated technique was used to quantify LGE and was 
displayed on a bullseye plot as relative enhanced area (percentage) per segment on the 16-
segment American Heart Association model. 
 
For the analysis of the RV LGE, a segmentation model was created using short axis images. 
Basal, mid and apical segments were identified using the papillary muscles as markers and 
divided into anterior, anterolateral, inferolateral and inferior segments for the basal and mid RV 
segments and as apical anterior and apical inferior segments for the RV apical segments.  
The amount of RV LGE was quantified visually as 0 (no LGE), 1 (some LGE), or 2 (high LGE) 
independently by 2 operators with 3 years of experience in CMR each (SR and HB). The 
operators’ RV LGE quantification differed initially in 2 segments. Following additional analysis 
of these segments, the reviewers reached a consensus. Analyses of the ECGI and CMR data were 
conducted independently with investigators blinded to the results of the other modality. 
 
Electrogram Analysis 
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Reconstructed unipolar epicardial EGMs were processed to compute local electrical measures. 
Activation times (ATs) were computed as the time of steepest negative time-derivative of 
voltage (-dV/dtmax) in the local QRS complex. Recovery times (RTs) were computed as the time 
of steepest positive time-derivative (dV/dtmax) during the T-wave 
15. Activation-recovery 
intervals (ARIs, a surrogate for local action potential duration) were computed as the difference 
between RT and AT. Supplemental Figure S2 defines these measures. ECGI-reconstructed ARI 
values were validated against direct intraoperative epicardial mapping in humans (Zhang et al. 
Online Supplement 16). Spatial gradient magnitudes of EGM measures were computed for each 
EGM as the absolute value of the change between neighboring EGMs divided by the distance 
between EGM locations, averaged across all neighbors. EGM amplitudes were computed as the 
peak-to-peak voltage during the QRS complex. Fractionation was quantified using the number of 
steep downward deflections between QRS onset and the start of the T-wave. Additional details 
of the fractionation quantification and sample EGMs are provided in Supplemental Figure S3. 
The earliest 10% of ATs were considered the epicardial initiation site of a PVC. PVC occurrence 
rates per EGM at a given epicardial site were computed as the number of times the EGM met the 
above criterion divided by the total number of beats recorded during the study. 
 
Statistical Analysis 
Fractionation values within anatomical segments are presented as z-scores compared to a group 
of 20 healthy adults. Electrical measures in the ARVC study population were compared to 
healthy controls using Wilcoxon rank-sum tests. Exercise changes were assessed using Wilcoxon 
signed-rank tests. Cohort data are presented as medians and quartiles. Substrate and PVC rate 
  
11/R3 
comparisons were performed using Spearman correlation coefficients computed using Matlab 
software (The MathWorks, Inc., Natick, Massachusetts, USA). 
 
 
Results 
 
Electrical Substrate at Rest 
Abnormal sinus rhythm activation and conduction were common in the ARVC patients. The 
normal epicardial activation pattern is well described 17 and a representative control is presented 
in Figure 1. Generally, the earliest epicardial activation appears as a breakthrough, most 
commonly in the anterior RV, and the basal lateral LV is usually the latest region to activate (Fig 
1A). The normal sinus activation of healthy adult hearts does not have regions of discontinuous 
conduction or fractionated EGMs (Fig 1A and 1B, left). In contrast to the normal activation 
sequence, we observed abnormal and varied epicardial breakthrough locations, regions of 
discontinuous conduction, and fractionated electrograms in the ARVC study population.  
 
Figures 2-4 present activation and conduction patterns seen in ARVC patients. In two patients 
with advanced disease (63 and 66 years old, respectively) we observed earliest epicardial 
breakthrough in the LV (Fig 2A and 3A). One of these patients had normal epicardial EGMs 
(Fig 2A), while we observed low-amplitude fractionated EGMs in the other (Fig 3A). ECGI 
resolved activation and conduction abnormalities in a 26-year-old patient who did not have any 
Major Task Force Diagnostic Criteria. In this patient, we observed fractionated EGMs and non-
uniform conduction near the earliest epicardial breakthrough site (Fig 4A). ARVC patients had 
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fractionation scores within anatomical regions that ranged from values within the control range 
(Fig 2B, top) to values which were several standard deviations above the control distribution 
(Fig 3B and 4B, top). While some patients had high fractionation scores, we did not observe 
EGMs in these patients with deflections after the QRS complex (late potentials) that are 
commonly associated with re-entrant arrhythmias (Fig 2A-4A). The abnormal conduction in 
ARVC patients compared to controls was reflected in statistically longer total duration of 
epicardial activation (p = 0.007, Control: 42 [36-47] ms, ARVC: 52 [44-64] ms) and steeper 
mean epicardial gradients of AT (p = 0.018, Control: 0.24 [0.21-0.28] ms/mm, ARVC: 0.31 
[0.26-0.37] ms/mm). 
 
Repolarization in ARVC patients was prolonged compared to controls, and this prolongation was 
often spatially heterogeneous. Figure 1B (right) presents a schematic map of mean ARI values 
in epicardial segments for a representative control. Control values were homogenous and fell 
within the range of values previously reported 17. In contrast, Figures 2B and 3B (middle) show 
prolonged ARI values in ARVC patients. As demonstrated in Figure 2B (top), regions of normal 
ARI values may co-exist with regions of long ARIs. Mean ventricular ARIs during resting sinus 
rhythm (Fridericia rate correction applied) were significantly longer than control values (p = 
0.014, Control: 241 [230-262] ms, ARVC: 275 [238-300] ms). While ARIs were prolonged in 
ARVC patients, we did not observe increased spatial gradients of repolarization or total duration 
of epicardial repolarization (Supplemental Table S4). 
 
The presence of T-wave inversion on clinical ECG (clinical ECG findings in Supplemental 
Table S2) was strongly associated with ARI prolongation. ARVC patients with T-wave 
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inversion (Fridericia rate correction applied) had significantly longer mean ARI values than 
those without inversion (p = 0.010, With Inversion: 300 [269-313] ms, Without Inversion: 238 
[231-262] ms). However, ECGI identified a patient without T-wave inversion whose mean 
epicardial ARI was longer than any control, as well as a patient with T-wave inversion whose 
mean epicardial ARI was within the lowest quartile of the control values (Supplemental Table 
S5). 
 
Electrical Substrate during Stress 
As expected, mean epicardial ARI (uncorrected for HR) shortened due to exercise (p < 0.001). 
Total RT (p = 0.002), mean epicardial RT gradients (p = 0.007), and mean EGM amplitude (p < 
0.001) also decreased due to exercise. Total AT, mean epicardial AT gradients, and fractionation 
were unaffected by exercise (Supplemental Table S6). 
 
Structural (CMR) Substrate 
Advanced LGE revealed a spectrum of scar burden in the ARVC patients. There was scar in 72% 
of ARVC patients agreeable to contrast. Three patients had isolated RV LGE, seven had isolated 
LV LGE, three had biventricular LGE, and five had no scar. Six patients in the study cohort had 
no Task Force CMR defects. Of these six, three had visible LV LGE. Panels B (bottom) and C 
of Figures 2-4 illustrate the broad spectrum of LGE observed in the study population. 
 
Relationship of Electrical and Structural Substrates 
LGE scar spatially co-localized with EP substrate abnormalities, and the relationship between 
CMR scar and EP abnormalities was stronger in the LV than in the RV. The amount of LV LGE 
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within anatomical segments correlated with EGM markers of abnormal depolarization including 
low amplitude EGMs, increased number of deflections per EGM, and increased AT spatial 
gradients. LV LGE correlated with prolonged resting ARI values and increase in ARI shortening 
during and post exercise (Supplemental Table S7). RV LGE values within anatomical segments 
did not correlate with EGM markers of abnormal depolarization, but did correlate with prolonged 
ARIs at rest and post-exercise. RV LGE correlated with ARI shortening due to exercise 
(Supplemental Table S8). 
 
The results from Patient 6 (Fig 2) and Patient 14 (Fig 3) illustrate the above findings. Patient 6 
has an RV anatomical scar that does not extend to the epicardium, as determined from LGE (Fig 
2C). The absence of scar on the epicardium is reflected in the local EGMs (EGM 1, Fig 2A), 
which appear normal. This is also reflected in the normal fractionation z-scores (Fig 2B, top). 
Patient 14 has a similar RV anatomical scar, which lacks clear epicardial involvement (Fig 3C). 
However, in this case, the ECGI reconstructed epicardial EGMs at this location (EGM 1, Fig 
3A) are low amplitude and fractionated, indicating EP abnormality at the epicardium. The same 
patient also has an LV scar which is visible on the epicardial aspect of the lateral LV. For this 
scar, the corresponding epicardial EGMs (EGM 2, Fig 3A) are fractionated, indicating 
coexistence of abnormal anatomical and EP substrates on the epicardium. 
 
Ventricular Ectopy 
Ventricular ectopy was common in the ARVC patients and occurred more frequently as heart 
rate increased following exercise. We observed PVCs in fifteen of twenty ARVC patients, with a 
total of 41 distinct morphologies. The sites of earliest epicardial activation of the PVCs were 
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spread across both ventricles, with greater involvement of RV and basal locations. A schematic 
diagram of the earliest epicardial activation sites for all PVC morphologies is provided in Figure 
5. 
 
The PVC rate within anatomical segments correlated with prolonged ARIs, ARI shortening due 
to exercise, low voltage EGMs, increased deflections per EGM, and LGE scar (all correlations p 
< 0.001). The PVC rate within anatomical segments did not correlate with increased gradients in 
AT, RT, or ARI. Figures 6 and 7 show the temporal occurrence and spatial location and 
propagation of PVCs in two patients. The substrates for these patients are presented in Figures 2 
and 3, respectively. Supplemental Table S9 summarizes the correlations between PVC rate and 
structural and EP substrate measures. 
 
Discussion 
This is the first evaluation of ECGI in ARVC patients. ECGI was sensitive enough to detect EP 
substrate differences between ARVC patients and healthy controls. By combining ECGI with 
LGE, we determined correlations between EP abnormalities and LGE scar. These correlations 
indicate that the EP abnormalities detected with ECGI are markers of disease progression. 
Importantly, new findings regarding properties of the EP and scar substrates included prolonged 
epicardial ARIs and a relationship of PVC rate within a region to repolarization, EP markers of 
scar, and LGE. 
 
ARVC Scar Substrate 
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Ventricular LGE was variable in location and extent. LV LGE was a more frequent finding than 
RV LGE. LV LGE co-localized with traditional markers of EP scar assessed using ECGI, as 
reflected by its correlation with lower voltage EGMs and increased fractionation. This finding 
mirrors prior ECGI studies that found regions of scar assessed with LGE or single-photon 
emission computed tomography to have lower voltage EGMs and increased fractionation 18. In 
the RV, we did not observe a strong relationship between LGE and traditional EP markers of 
scar. This is consistent with prior work comparing invasive EP mapping to RV LGE, which 
found that nearly 50% of electrical scar substrates in the RV were not confirmed by LGE 19. 
Prior studies have suggested that the absence of RV LGE findings could be attributed to the thin 
RV wall, which complicates LGE in the RV 20. Alternatively, it is possible that EP abnormalities 
in the RV manifest in the presence of minimal scar or scar that is diffuse and not easily resolved 
with current imaging techniques.  
 
Prolongation of Repolarization 
There are multiple mechanisms which could contribute to the ARI prolongation observed in this 
study. Functional changes in ionic currents due to ARVC mutations could contribute to 
prolonged repolarization. Studies linking INa current to Plakophilin-2 mutations provided the first 
evidence that ARVC may have some features of a channelopathy 21. While the focus of research 
efforts in this area has largely been on depolarization, it is possible that repolarizing currents are 
altered as well. Kv1.5 channels localize to the intercalated disc and associate with Nav1.5 
22,23, 
and Kv1.5 function depends on N-cadherin, an intercalated disc protein 
24. A mutation in KCNE2 
that inhibits trafficking of Kv1.5 to the intercalated disc causes prolonged repolarization 
25. While 
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we are unaware of direct evidence suggesting that this mechanism is involved in ARVC, it is an 
interesting avenue for exploration. 
 
Another mechanism which may contribute to prolonged repolarization is progression of the heart 
failure phenotype associated with ARVC. Heart failure is a known end-stage complication of 
ARVC 4, but systolic impairment of varying degrees can appear in either or both ventricles in the 
absence of clinical heart failure 10. Action potential prolongation is a hallmark of heart failure 
along with functional downregulation of potassium currents, slow conduction, and abnormal 
calcium homeostasis 26. It is possible that these features develop in ARVC patients either 
globally or locally as the disease progresses and surviving myocardium is subjected to increasing 
strains because of fibrofatty tissue replacement. 
 
Finally, myocardial uncoupling can increase the effects of any action potential duration 
prolongation mechanisms. Myocardial uncoupling facilitates gradients in repolarization by 
decreasing the electrotonic coupling between cells 27. Fibrofatty replacement acts to uncouple 
cells by decreasing the local density of excitable cells. Reduction in the number and size of gap 
junctions in the intercalated disc causes further uncoupling in ARVC, and has been reported even 
in histologically normal regions of myocardium 6. 
 
In our data, ARI prolongation correlated with LGE in both ventricles. This suggests that the 
uncoupling effect of the scar, altered mechanical strains in regions of scar, or both may be 
important to the development of prolonged repolarization. The uncoupling effect of ventricular 
scar could also contribute to the correlation we observed between stress-related ARI shortening 
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and LGE in both ventricles, as both rate increase and sympathetic stimulation have a greater 
effect on cardiomyocytes that are less electrically coupled. While our population size is not 
sufficient to draw conclusions about the age progression of the ARVC phenotype, we note that 
the group included two patients in their twenties, both of whom had ARI values within the 
normal range. This suggests that action potential prolongation in ARVC patients may develop as 
the overall phenotype progresses. Mean epicardial ARIs were generally longer in patients with 
precordial lead T-wave inversion. However, there were patients with and without T-wave 
inversion who were exceptions to this relationship, indicating that ECGI offers improved 
sensitivity and specificity for detecting prolonged repolarization. Additionally, ECGI provides 
spatial information about ARI prolongation, which was spatially heterogeneous in ARVC. 
 
Arrhythmia Triggers (PVCs) 
The ability of ECGI to panoramically map the whole heart in a single beat allowed us to localize 
PVCs, determine the frequency of each unique PVC morphology, and correlate ectopic 
frequency with the EP and scar substrates. The overall rate of PVCs was increased by exercise. 
We found that PVC rate within anatomical segments correlated with local ARI prolongation, 
increased ARI shortening due to exercise, low voltage EGMs, fractionated EGMs, and LGE. 
 
The hallmark finding of progressive scar formation in ARVC is compatible with the possibility 
of re-entrant circuit formation. Prior work demonstrated conduction slowing at elevated heart 
rates in ARVC patients 28. In the present study, we found evidence of slow conduction in the 
form of longer total activation times and steeper activation gradients relative to controls. 
However, we did not observe the dynamic conduction slowing at elevated HRs that Finlay et al. 
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reported 28. This discrepancy could be attributable to the difference in HRs investigated. In the 
present study, patients exercised to a peak HR of 120 beats/min, whereas the patients in the 
Finlay et al. study were paced at an interval just below the ventricular refractory period. 
 
The combination of scar, slow conduction, and prolonged repolarization could facilitate 
unidirectional block and reentrant arrhythmia. Important signatures of re-entrant arrhythmia are 
EGM fractionation and late potentials. We did not observe late potentials in the reconstructed 
EGMs. This stands in contrast to ECGI studies of post-infarction scar-related ventricular 
tachycardia, which found a high prevalence of late potentials with re-entry circuits closely 
related to the EP substrate 29. While this could indicate that re-entrant arrhythmias are less 
prevalent in ARVC, it is important to note the significant differences in the anatomy of the scars 
in each population. Post–infarction scars are often large and heterogeneous, with large islands of 
surviving myocardium, especially in the border zone. The ARVC scar substrate, on the other 
hand, accumulates gradually over time and is typically diffuse, originating from the epicardium. 
It is possible that the lower regional density of surviving myocardium in ARVC scar makes it 
difficult to resolve late potentials in EP mapping of ARVC patients. 
 
Focal mechanisms may cause arrhythmia triggers in ARVC patients. Focal triggered activity is 
commonly observed in isolated myocytes in the form of early afterdepolarizations or delayed 
afterdepolarizations. Early afterdepolarizatons at plateau potentials are caused by recovery and 
re-activation of ICa, with the delayed rectifier currents, IKr and IKs, playing an important role 
30.  
We observed that PVC rate correlated with regions of prolonged ARI, a surrogate for local action 
potential duration, including during stress when ICa is augmented by beta-adrenergic stimulation. 
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Action potential duration prolongation increases the window for ICa re-activation and early 
afterdepolarization formation. In the intact heart, electrotonic coupling between myocytes acts as 
a current sink for depolarizing currents. Reduced coupling, caused by scar and gap junction 
abnormalities in ARVC, can increase the likelihood of focal activity by decreasing the current 
sink effect. The observed correlation between PVC rate and electrical and LGE markers of scar 
suggests that an uncoupling effect is present at PVC initiation sites. It is interesting to note that 
Myles et al. 31 found that focal activity was more common in the RV, which they attributed to 
reduced coupling in the thin RV wall compared to the LV. In our study, we found greater overall 
ectopy in the RV. 
 
  
Clinical Implications 
The progressive nature of ARVC and its early concealed phase complicate diagnosis and 
treatment. CMR currently plays a valuable role in the evaluation of ventricular structure and 
function. The current Task Force criteria do not include LGE, but acknowledge that it may be 
included in future revisions 3. Our data show that combined ECGI and LGE could increase the 
sensitivity for detecting substrate abnormalities in ARVC patients, including young patients with 
little or no Task Force MRI and ECG criteria. LGE and ECGI are compatible with the current 
use of CMR in the diagnosis and longitudinal assessment of ARVC. These imaging techniques 
can be performed in addition to the conventional CMR assessment to provide a thorough 
characterization of structural, functional, and EP abnormalities. In the present study, we report a 
spectrum of abnormalities using these techniques and demonstrate a relationship between the 
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imaged substrates and ventricular ectopy. Since ventricular ectopy may play a causal role in 
triggering arrhythmias, combined ECGI and LGE may have a role in risk stratification. 
 
Limitations 
This study is a first evaluation of combined ECGI and LGE in ARVC patients and, therefore, 
evaluated a relatively small group of twenty patients. Because CMR is commonly 
contraindicated in patients with implanted devices, we only recruited patients without ICDs. 
While this choice enabled us to image LGE in the study cohort, a drawback is that none of the 
patients in this study had prior episodes of ventricular tachycardia. Therefore, this study cohort is 
not well-suited for evaluating sudden cardiac death risk stratification. Further studies are 
necessary to explore this application of these techniques. The current study evaluated patients 
ranging in age from 24 to 75 years old; however, only three patients were younger than 41 years 
old. Future studies should evaluate whether this approach can detect the presence of ARVC in 
young, asymptomatic and genotype-positive individuals. Larger studies of a wide range of ages 
and genotypes are important for exploring the progression of the disease, including how the EP 
and scar substrates change over time. Prior studies demonstrated that strain imaging may be 
effective for detecting the early stages of ARVC and for risk stratification 32,33. Future studies 
could combine ECGI and strain imaging into a multi-modality approach for ARVC diagnosis 
and risk stratification. Exercise and LGE data were collected from the ARVC patients, but not 
controls. These data are needed to establish ranges for healthy controls. Additional data are 
necessary to determine the specificity of ECGI and LGE criteria for diagnosis of ARVC. 
 
Conclusion 
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ECGI in combination with advanced LGE reveals a spectrum of electrical and structural 
substrate abnormalities in ARVC patients. This combination may improve sensitivity for 
detecting ARVC substrate abnormalities. These data suggest a role for combined ECGI and LGE 
in early diagnosis, non-invasive follow-up, and risk stratification of ARVC patients.  
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Tables 
 
Table 1 
 
Patient ID Age Gender Mutation Major Criteria Minor Criteria 
1 59 M JUP 1 1 
2 63 M PKP2 1 3 
3 54 F PKP2 2 3 
4 44 M DSP 1 3 
5 55 M DSP 1 5 
6 63 M PKP2 3 3 
7 59 M DSP 1 3 
8 69 F PKP2 0 2 
9 61 M DSP 1 2 
10 41 F DSP* 1 1 
11 49 F PKP2 3 2 
12 60 M DSG 3 2 
13 26 M PKP2 0 3 
14 66 M PKP2 2 1 
15 54 M PKP2 2 0 
16 74 M DSG 1 3 
17 24 M DSP 1 0 
18 54 M Negative 2 2 
19 39 M Negative 2 2 
20 75 M Negative 2 3 
 
 
ARVC patient characteristics including Task Force Major and Minor Criteria (numbers indicate 
how many Major and Minor Criteria were observed). Mutation abbreviations: Plakoglobin 
(JUP), Plakophilin-2 (PKP2), Desmoplakin (DSP), Desmoglein (DSG). Asterisk indicates 
variant of unknown significance.  
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Figure Legends 
 
 
Figure 1 
Electrical substrate in a healthy adult. (A) Sinus rhythm activation with a typical RV epicardial 
breakthrough (asterisk) and normal conduction. RV (1) and LV (2) unipolar EGMs have a 
normal morphology free of fractionation. (B) Schematic maps of normal electrical properties in 
anatomical regions based on 20 control subjects. Left: fractionation z-score.  Right: Fridericia-
corrected ARI. The maps show absence of fractionation and ARI values within the normal range. 
AT: activation time. RA: right atrium. LA: left atrium. RV: right ventricle. LV: left ventricle. 
ARI: activation-recovery interval. EGM: electrogram. 
 
Figure 2 
Electrical substrate of a patient (Patient 6) with advanced disease and a high PVC rate (18.69%). 
(A) Ventricular epicardial breakthrough during sinus rhythm was abnormal, with earliest 
activation originating from the basal inferior LV (asterisk). RV (1) and LV (2) unipolar EGMs 
had normal QRS morphology. (B) EGM fractionation was not abnormal compared to controls 
(top). Fridericia-corrected ARIs were prolonged compared to control values (middle). 
Concentrated LGE was visible in the inferior RV (bottom). (C) MRI image of extensive LGE, 
which was confined to the subepicardial RV (indicated by yellow arrows). PVC: premature 
ventricular contraction. 
 
Figure 3 
  
30/R3 
Electrical substrate of a patient (Patient 14) with biventricular disease and a moderate PVC rate 
(1.11%). (A) Sinus rhythm breakthrough was abnormal, with earliest epicardial activation 
originating from the basal lateral LV (asterisk). RV (1) and LV (2) unipolar EGMs were 
fractionated (note the voltage scale of low-amplitude EGM 1). (B) Regions of high fractionation 
were present in both ventricles (top), and Fridericia-corrected ARI values were prolonged 
compared to control values (middle). LGE was visible in both ventricles (bottom). (C) MRI 
image of LGE showing scar in both ventricles (yellow arrows). 
 
Figure 4 
Electrical substrate of a 26-year-old male (Patient 13) with early disease and no observed PVCs. 
(A) Sinus rhythm epicardial breakthrough occurred in the inferolateral RV (asterisk in inset) with 
early activation of the RV free wall. There was a region of non-uniform conduction and 
fractionated unipolar EGMs (1) between these sites. Remote LV unipolar EGM (2) had a normal 
morphology. (B) Fractionation in the RV was much greater than control values (top) while 
Fridericia-corrected ARI values were within the normal range of controls (middle). Minimal 
LGE was visible in the LV (bottom). (C) MRI showed minimal abnormalities (arrow). 
 
Figure 5 
Schematic diagram of earliest epicardial activation of all observed PVC morphologies. Each 
marker represents a unique PVC morphology, with the number indicating the number of times 
the morphology was observed during the study. Marker color and shape identify patient ID 
(indicated below diagram). Sites near the epicardial aspect of the septum are shown on the edge 
of the RV. 
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Figure 6 
PVC onset and initiation sites of a patient (Patient 6) with a high PVC burden (18.69%). (A) 
Time-course of observed PVCs in relation to exercise and schematic map of PVC initiation sites. 
The different PVC initiation sites are labeled A, B, and C and color coded. PVCs occurred only 
after the onset of exercise, and morphology C appeared only once near peak HR (B) Activation 
isochrone maps of the three distinct PVC morphologies observed in this patient.  
Asterisks indicate PVC initiation sites. Morphology B showed very a broad region of early 
epicardial activation, indicating a possible sub-epicardial origin and possible conduction system 
involvement. HR: heart rate. 
 
Figure 7 
PVC onset and initiation sites of a patient (Patient 14) with a moderate PVC burden (1.11%). (A) 
Time-course of observed PVCs in relation to exercise and schematic map of PVC initiation sites. 
Note that morphology C is partially obscured in the post-exercise recording period. (B) 
Activation isochrone maps of the three distinct PVC morphologies observed in this patient. 
Asterisks indicate PVC initiation sites.   
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Figure 3 
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